Sugi Predict

Sugi Predict / Compounds / SCHEMBL5344959

SCHEMBL5344959

SCHEMBL5344959

CNC1CCN(S(C)(=O)=O)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.50
▸ EPHX2 P34913 3/20 0.45
▸ KDM1A O60341 1/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ FABP6 P51161 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ SMYD3 Q9H7B4 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17780281 0.92 FABP6 (0.54) TP53EPHX2KDM1AEPHX1FABP6
SCHEMBL962569 0.87 TP53 (0.43) TP53EPHX2KDM1AEPHX1FABP6
SCHEMBL962299 0.87 TP53 (0.43) TP53EPHX2KDM1AEPHX1FABP6
SCHEMBL12225575 0.87 TP53 (0.43) TP53EPHX2KDM1AEPHX1FABP6
SCHEMBL9034989 0.82 CA1 (0.42) TP53EPHX2KDM1AEPHX1FABP6
SCHEMBL23838711 0.81 TP53 (0.31) TP53EPHX2KDM1AEPHX1TSHR
SCHEMBL23862929 0.81 ALDH1A1 (0.57) TP53LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL12820051 0.80 TP53 (0.48) TP53EPHX2KDM1AEPHX1FABP6
SCHEMBL13939596 0.80 EPHX2 (0.46) TP53EPHX2TSHRSMYD3L3MBTL1
SCHEMBL29259766 0.80 TP53 (0.48) TP53EPHX2KDM1AEPHX1FABP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 — — US disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 — — US disclosed
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2024-06-25 — — US disclosed
CN-117940427-A Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof 卡里克治疗有限公司 2024-04-26 — — CN disclosed
WO-2023078398-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2023-05-11 — — WO disclosed
US-20230147603-A1 HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS PROSETTA BIOSCIENCES, INC. 2023-05-11 — — US disclosed
WO-2023069770-A1 NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS PROSETTA BIOSCIENCES, INC. (US) 2023-04-27 — — WO disclosed
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 — — US disclosed
US-20220009933-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-13 — — US disclosed
CN-113923988-A Substituted arylmethyl and heteroarylmethyl ureas, analogs thereof, and methods of using the same 爱彼特生物制药公司 2022-01-11 — — CN disclosed
US-7220736-B2 Pyrimidine compounds TANABE SEIYAKU CO., LTD. (JP) 2007-05-22 — — US disclosed
US-7220736-B2 Pyrimidine compounds TANABE SEIYAKU CO., LTD. (JP) 2007-05-22 — — US disclosed
US-7157472-B2 Neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-01-02 — — US disclosed
US-7157472-B2 Neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-01-02 — — US disclosed
US-20040102474-A1 New neuropeptide Y Y5 receptor antagonists STAMFORD ANDREW W (US) 2004-05-27 — — US disclosed
EP-1418913-A1 SUBSTITUTED UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS Schering Corporation (US) 2004-05-19 — — EP disclosed
WO-2003009845-A9 SUBSTITUTED UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORP (US) 2004-03-11 — — WO disclosed
US-6667319-B2 Benzyl-cyclohexyl-uredo-p-piperidinyl amido- or sulfamido-derivatives; obesity, metabolic disorders, eating disorders SCHERING-PLOUGH CORPORATION 2003-12-23 — — US disclosed
US-20030207860-A1 Neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION 2003-11-06 — — US disclosed
WO-2003009845-A1 SUBSTITUTED UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 TP53 332/4885EPHX2 4689/4885KDM1A 2469/4885
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics MAVS, SARS1, ZC3HAV1 TP53 1921/4885EPHX2 2862/4885KDM1A 4001/4885
US-20220009933-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR IRAK4, IRAK1, IRAK2 TP53 962/4885EPHX2 4010/4885KDM1A 156/4885
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 TP53 65/4885EPHX2 4696/4885KDM1A 2428/4885
US-20040102474-A1 New neuropeptide Y Y5 receptor antagonists NPY5R, NPY1R, NPY2R TP53 4798/4885EPHX2 2745/4885KDM1A 774/4885
US-20030207860-A1 Neuropeptide Y Y5 receptor antagonists NPY5R, NPY1R, NPY2R TP53 4747/4885EPHX2 2436/4885KDM1A 736/4885
US-20230147603-A1 HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS MAVS, SARS1, ZC3HAV1 TP53 1921/4885EPHX2 2862/4885KDM1A 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.